Influenza Session

Robert L. Atmar, MD
Chair, Influenza Work Group

Advisory Committee on Immunization Practices
June 24, 2020
Influenza Work Group

**ACIP Members**
Robert Atmar (Chair)
Kevin Ault
Hank Bernstein
Peter Szilagyi
Keipp Talbot

**Ex Officio Members**
Michael Cooper (NIH)
Cynthia Nolletti (FDA)
Chris Roberts (NIH)
Susan Wollersheim (FDA)

**Consultants**
Ed Belongia
Chip Walter
Jeff Duchin
Wendy Keitel
Jamie Loehr
Mark Mulligan
Kathy Neuzil

**Liaison Representatives**
Sarah Coles (AAFP)
Buddy Creech (PIDS)
Sarah Despres (Consumer Representative)
Sandra Fryhofer (ACP; AMA)
Ian Gemmill (NACI)
Denise Jamieson (ACOG)
Marie-Michèle Léger (AAPA)
Susan Lett (CSTE)
Flor Munoz (AAP)
William Schaffner (NFID)
Rob Schechter (AIM)
Ken Schmader (AGS)
Patsy Stinchfield (NAPNAP)
Tamara Sheffield (AHIP)
Kelsey Young (NACI)
Matthew Zahn (NACCHO)
Recap of Influenza Session, February 2020

- Overview of early 2019-20 season influenza activity
- Early season 2019-20 influenza vaccine effectiveness estimates
- Presentation from Seqirus of pre-licensure study of quadrivalent adjuvanted inactivated influenza vaccine, Fluad Quadrivalent
  - Licensed by FDA in February 2020
- Presentation of safety data from a comparative RCT of high-dose and adjuvanted inactivated influenza vaccines among older adults
Recent Work Group Discussion

- Development of proposed 2020-21 ACIP Influenza Statement
Agenda Overview

- 2019-20 influenza activity, vaccine effectiveness, and safety updates
- Work Group considerations and proposed 2020-21 recommendations